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Mycophenolate mofetil reduces myofibroblast infiltration and Fibrosis contributes to the progression of renal dam-
collagen III deposition in rat remnant kidney. age and is the final common pathway for almost all forms
Background. Myofibroblasts have been shown to play a piv- of kidney diseases. However, the mechanisms underlyingotal role in the synthesis of extracellular matrix components
its development remain largely unknown. Cellular eventsin several animal models of renal fibrosis. The purpose of
such as cell proliferation, cell differentiation, productionthe present study was to investigate whether mycophenolate
mofetil (MMF) reduces interstitial myofibroblast infiltration of inflammatory cell mediators, as well as mechanical
and collagen III deposition in 5/6 nephrectomized rats. factors have been well identified in inducing renal fibrosis
Methods. Forty-five Wistar rats underwent 5/6 renal ablation [1–4]. Among them, cell differentiation into myofi-and received by daily oral gavage either vehicle (N 5 20) or
broblasts is one of the key cellular events initiating theMMF (N 5 25) during the 60 days following surgery. Groups
development of organ fibrosis [5]. These cells appear toof five treated and five untreated rats were killed at two, four,
and eight weeks after subtotal nephrectomy. Four untreated participate actively in tissue repair, but the production
and three treated rats were killed at week 12, one month after of extracellular matrix ultimately reduces the filtration
treatment withdrawal. At the time of sacrifice, proteinuria,
surface area in the kidney. In addition, these cells are ableplasma, and urine creatinine were determined. Immunohisto-
to contract [6] and are characterized by the presence ofchemistry was performed on renal tissue for a-smooth muscle
actin (a-SMA), a cytoskeletal marker of myofibroblasts, for cytoplasmic microfilament bundles expressing a-smooth
type III collagen, and for proliferating cell nuclear antigen muscle actin (a-SMA), the actin isoform characteristic
(PCNA). Moreover, in order to study the in vitro effects of of contractile vascular smooth muscle cells [7].
MMF on fibroblast proliferation, rat fibroblasts were cultured
Mycophenolate mofetil (MMF) is a specific inhibitorin the presence or absence of mycophenolic acid (MPA).
of inosine monophosphate deshydrogenase involved inResults. At all periods studied, MMF treatment improved
renal functional parameters and progressively decreased rem- de novo purine synthesis and a suppressor of both
nant kidney hypertrophy and glomerular volume increment. T- and B-lymphocyte proliferation. Thus, MMF is used
Proliferating cells in renal tubules, interstitium, and glomeruli, as an immunosuppressor in the prevention of acute [8, 9]as well as interstitial myofibroblast infiltration and interstitial
and chronic rejection after transplantation [10]. Interest-type III collagen deposition, were also significantly reduced by
ingly, MMF is an immunosuppressive drug that is alsoMMF treatment. In addition, MPA exhibited a dose-dependent
inhibitory effect on in vitro proliferation of rat fibroblasts. known to have an effect on cells outside of the immune
Conclusion. Reduction of interstitial myofibroblast infiltra- system and particularly an antiproliferative effect on vas-
tion may be an important event by which MMF significantly
cular smooth muscle cells [11]. MMF has been shown toprevents renal injury following subtotal renal ablation. Thus,
inhibit in vivo intimal smooth muscle cell hyperplasiaour results suggest that MMF could be useful to limit the
progression of chronic renal disease toward end-stage renal after balloon injury [12]. Furthermore, an inhibitory ef-
failure. fect of MMF on growth factor-induced proliferation of
vascular smooth muscle cells has been reported in vitro
[13]. Thus, we hypothesized that MMF could act on cellu-Key words: cell proliferation, chronic renal disease, a-smooth muscle
actin, fibrosis, subtotal nephrectomy. lar proliferation and/or myofibroblast differentiation and
then could reduce extracellular matrix accumulation. ToReceived for publication April 20, 1999
test this hypothesis, (1) we used the rat model of nonim-and in revised form December 30, 1999
Accepted for publication February 4, 2000 munologic progressive glomerulosclerosis obtained after
5/6 renal mass reduction [14], and studied the effects ofÓ 2000 by the International Society of Nephrology
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MMF administration on myofibroblast infiltration and Preparation of MMF and MPA
type III collagen deposition in renal cortical interstitium, The solubility of MMF is low in aqueous solution, pH
and (2) we examined the in vitro effect of mycophenolic 7, and increases at lower pH values. A vehicle solution,
acid (MPA) on the proliferation of rat fibroblasts. pH 3.5, was prepared using benzyl alcohol, polysorbate
80, sodium carboxymethylcellulose, and water. The mix-
ture was left overnight under magnetic stirring to dis-METHODS
solve properly. Before gavage, MMF was added to the
Animal procedures vehicle solution and sonicated. For in vitro studies, MPA
(Sigma, Saint-Quentin Fallavier, France), the metabolicForty-five Wistar rats (200 to 220 g) obtained from
active form of MMF was diluted in methanol as stockIffa-Credo (St. Germain sur l’Arbresle, France) were
solutions (10 and 100 mmol/L) before its addition inused in the study. Throughout the study, all rats were
culture medium.fed ad libitum with rat chow containing 16% protein
(UAR A04; Usine d’Alimentation Rationnelle, Ville-
Biochemical parametersmoison sur Orge, France) and had free access to tap
Plasma and urine creatinine concentrations were as-water. They were housed, five per cage, under controlled
sessed by a colorimetric method, using the Jaffe reactionconditions of temperature (21 6 18C), humidity (60 6
in autoanalyzer methodology. The creatinine clearance10%), and light (12-hour light/dark cycle). All proce-
was calculated by using standard formula CCr 5 UCr 3dures were carried out in accordance with our institu-
V/PCr and was expressed as mL/min/100 g kidney weight.tional guidelines for animal care. Under halothane anes-
Twenty-four–hour protein excretion was measured afterthesia (2% in oxygen), surgical renal mass reduction was
precipitation by using a colorimetric reaction with pyro-performed in two steps: Two thirds of the right kidney
gallol red and ionic molybdates (Biotrol Diagnostic,was first removed, followed one week later by the abla-
Chennevie`res les Louvres, France).tion of the left kidney. After the surgery, the rats were
divided into two groups: One (N 5 25) received MMF Morphologic and morphometric studies
(Roche Laboratories, Palo Alto, CA, USA) by daily
Transverse paraffin sections (3 mm) of the kidney weregastric gavage, and the other (N 5 20) received the same
stained with Sirius red for collagen identification. Inter-volume of vehicle by the same route of administration.
stitial fibrosis was semiquantitatively scored on a scaleSince MMF is not soluble in water, a vehicle at pH 3.5
of 0 to 41 by two independent observers (C.B., B.M.)was prepared (discussed later in this article). The dose
at low-power view (3100; 0, no changes; 11, changesof MMF used was 25 mg/kg/day during the first three
affecting ,25% of specimen area; 21, changes affecting
weeks, and thereafter it was reduced to 20 mg/kg/day
25 to 50% of specimen area; 31, changes affecting 50
because of side effects (Results section).
to 75% of specimen area; 41, changes affecting 75 to
Five treated and five untreated rats were randomly 100% of specimen area).
chosen to be sacrificed after two, four, or eight weeks The average glomerular tuft volume was estimated, at
of treatment. To study the possible persistent effect of each time of sacrifice, by the method of Weibel at a final
MMF, three treated and four untreated rats were sacri- magnification of 400 under a micrometric ocular grid
ficed after eight weeks of treatment, followed by four [15]. The mean glomerular cross-sectional area (Ag) was
weeks during which no administration of MMF or vehi- determined for each rat by averaging approximately 50
cle, respectively, was done. Body weight was measured glomerular sections. Individual glomerular volumes (Vg)
three times a week. Before sacrifice, 24-hour urine collec- was calculated as Vg 5 1.25 · (Ag)3/2 [16].
tions were performed after one day of habituation to
the metabolic cages for protein and creatinine determi- Immunohistochemistry
nation. The day after urine collection, rats were anesthe- Monoclonal antibodies used were directed against the
tized by pentobarbital in order to collect blood by aortic following antigens: the proliferating cell nuclear antigen
puncture and to remove remnant kidney. The kidney (PCNA), which is expressed by proliferating cells in the
was weighed and prepared for histologic studies: One G1, S, and G2 phases of the cell cycle (clone PC10; Dako,
part was fixed in 10% formalin and embedded in paraffin, Trappes, France), and the a-SMA isoform, a cytoskeletal
and the other part was snap frozen into liquid nitrogen marker of myofibroblastic differentiation [7]. For type
and stored at 2808C. Kidney tissue removed at the time III collagen, we tested a rabbit polyclonal antibody to rat
of the first step of the renal mass reduction was normal type III collagen [17] and a mouse monoclonal antibody
and considered below as control tissue. After collection, directed against type III collagen purified from human
urine and plasma were divided into aliquots and stored placenta (clone III 68G1), its specificity and reactivity
toward rat type III collagen being assessed by immuno-at 2208C.
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fluorescence on skin and by enzyme-linked immunosor- through 10. Fibroblast proliferation was assessed by a
biocolorimetric assay (MTT) [19], in quadruplicate forbent assay (ELISA; D.J.H., manuscript submitted). Since
the quality of staining was better with the monoclonal each MPA concentration. Fibroblasts were seeded at a
concentration of 1 3 104 cells/well and then incubatedantibody in preliminary experiments, we used it for this
study. Immunohistochemistry was performed on paraf- for 72 hours without or with different concentrations of
MPA (1, 10, 100, and 500 mmol/L) in FCS 10%. Atfin-embedded sections (3 mm) for a-SMA and PCNA
and on frozen tissue for type III collagen. Briefly, endog- the end of incubation, MTT (50 mg/well in phosphate-
buffered saline, pH 7.4) was added for four hours. Theenous peroxydase was inactivated with 0.3% H2O2 in
methanol for 20 minutes. To facilitate PCNA antigen medium was then removed and 150 mL/well of an etha-
nol-dimethyl sulfoxide solution (ethanol-DMSO; 1:1)retrieval, sections were treated with three rounds of
microwave radiation, each lasting five minutes, in 10 were added to dissolve the dark blue crystals. The color
reaction was read at 750 nm and expressed as opticalmmol/L sodium citrate (pH 5 6) at 750 W power. To
block nonspecific antibody sites, sections were preincu- density.
bated with normal goat serum (Dako) for 30 minutes.
Statistical analysisThereafter, sections were incubated with the primary
antibody during 30 minutes at room temperature for Data are expressed as mean 6 SEM and were com-
pared among groups by one-way analysis of variancePCNA and a-SMA antibodies and overnight at 48C for
monoclonal type III collagen antibody. Sections were (ANOVA), followed by Fischer’s PLSD test. Linear
regression analysis was used to test the relationshipsthen consecutively incubated with the biotinylated sec-
ondary antibody for 30 minutes and streptavidin biotinyl- between biochemical parameters and immunohistochem-
ical data. A P value , 0.05 was considered to be statisti-ated peroxydase complex (streptABC/HRP; Dako) for
30 minutes. Peroxidase activity was revealed using 3-39 cally significant.
diaminobenzidine tetrahydrochloride in phosphate-buf-
fered saline containing H2O2 for 10 minutes. Sections RESULTS
were finally counterstained with Harris hematoxylin,
Body weight and side-effectswashed in water, and coverslipped.
During the first three weeks, the dose of MMF used
Quantitation of the immunostaining was 25 mg/kg/day, but because of a tendency for body
weight loss, the dose was then reduced to 20 mg/kg/day.Proliferating cell nuclear antigen-positive cells were
counted, in a blind fashion, separately in interstitium, Seven treated rats and one untreated rat died. Five out
of the seven treated rats died very early (days 2, 4, andtubules, and glomeruli from at least 10 consecutive high-
power fields under 3200 magnification. Data were ex- 5), and at the autopsy, they showed a gastric dilation
without emptying. The two other treated rats died laterpressed in interstitium and tubules as the mean number
(6SEM) of positive cells per field and in glomeruli as at days 18 and 44 after the start of the treatment, and
showed diarrhea associated with body weight loss. Onethe mean number (6SEM) of positive cells per glomeru-
lus. The surface area labeled with a-SMA or type III untreated rat died because of an hemorrhagic complica-
tion of the surgery. In addition, hemoglobinemia andcollagen antibodies was evaluated by quantitative image
analysis using a Quantimet 600 (Leica, Cambridge, UK) hematocrit measured at the time of sacrifice were found
decreased in the treated group compared with the un-as previously described [18]. Briefly, the percentage of
the stained area was calculated as the ratio of suitable treated group whatever the dose used. This anemia to-
tally reversed one month after treatment withdrawalbinary thresholded image and the total field area. For
each kidney, the mean staining value was obtained by (Table 1).
analysis of 20 different fields (3200) excluding glomeruli
Renal compensatory growth after subtotaland vessels. Quantitations were done twice, indepen-
nephrectomydently, and interassay variations were not significant.
After subtotal nephrectomy, the weight of the remnant
In vitro studies kidney increased with time in both groups, but the incre-
ment was much lower in treated than in untreated ratsRat fibroblasts, obtained from skin explants, were cul-
tured in tissue culture flasks in the presence of Dulbec- (Table 2). Interestingly, kidney weight did not increase
in the treated group between weeks 8 and 12, the periodco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS 10%; GIBCO, Cergy during which MMF had been withdrawn, while it kept
increasing in the untreated group. Similarly, glomerularPontoise, France) and antibiotics. Cultures were incu-
bated until confluent monolayer and then subcultured volume increased with time in both groups. However,
the increment was significantly lower in treated than inafter trypsinization (trypsin-EDTA solution; GIBCO).
Experiments were carried out on cells in passages 2 untreated rats (Table 2).
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Table 1. Body weight and biochemical characteristics in treated and untreated rats at 2, 4, 8 and 12 weeks after subtotal nephrectomy
Week 2 Week 4 Week 8 Week 12
Body weight g
Treated 25269 (5) 30965 (5) 368614 (5) 414622 (3)
Untreated 257611 (5) 316610 (5) 38767 (5) 419611 (4)
Hemoglobinemia g/L
Treated ND 10.661.3 (5) 8.061.5 (5)b 14.960.6 (3)
Untreated ND 13.560.3 (5) 15.060.7 (5) 15.660.5 (4)
Hematocrit %
Treated 31.460.8 (5) 30.663.8 (5) 22.063.9 (5)b 41.562.7 (3)
Untreated 36.061.2 (5) 38.260.8 (5) 40.662.3 (5) 42.060.8 (4)
Plasma creatinine lmol/L
Treated 9565 (5) 9366 (5) 9166 (5)a 9368 (3)a
Untreated 141626 (5) 106614 (5) 7163 (5) 13569 (4)
Values are expressed as mean 6 SEM. Treatment was given for the first eight weeks and withdrawn thereafter from week 8 to week 12.
aP , 0.05, bP , 0.005 vs. untreated rats
Table 2. Remnant kidney weight and histologic characteristics of treated and untreated rats at 2, 4, 8 and 12 weeks after subtotal nephrectomy
Week 2 Week 4 Week 8 Week 12
Remnant kidney weight g
Treated 0.7060.05 (5) 0.9660.03 (5) 1.1660.06 (5)a 1.1060.005 (3)b
Untreated 0.7460.05 (5) 1.0560.04 (5) 1.5060.12 (5) 1.8160.14 (4)
Glomerular volume 10 6 lm3
Treated 0.9660.12 (5) 0.9360.06 (5) 1.5860.19 (5)a 1.7660.01 (3)c
Untreated 1.060.1 (5) 1.0660.14 (5) 2.1160.09 (5) 2.2460.03 (4)
Interstitial fibrosis (score)
Treated 1.460.2 (5)a 1.560.3 (5)b 1.660.3 (5) 1.860.1 (3)c
Untreated 2.260.2 (5) 2.860.2 (5) 2.660.4 (5) 460 (4)
Values are expressed as mean 6 SEM. Treatment was given for the first eight weeks and withdrawn thereafter from week 8 to week 12.
aP , 0.05, bP , 0.01, cP , 0.005 vs. untreated rats
Biochemical parameters Interstitial myofibroblast accumulation
In normal renal tissue removed at the time of the firstAfter subtotal nephrectomy, untreated rats developed
a progressive proteinuria from weeks 2 through 12 that step of the surgery, no or only few myofibroblasts were
detected. a-SMA was essentially and normally expressedbecame severe with time (from 79.2 6 24.4 mg/day at
week 2 to 190.4 6 41.3 mg/d at week 12). In comparison, in vascular smooth muscle cells. Two weeks after subtotal
nephrectomy, myofibroblasts were well identified infil-the MMF-treated rats at each period showed a lower
urinary protein excretion (from 23.7 6 4.3 mg/day at trating renal interstitium. The interstitial immunostain-
ing was 12-fold higher in remnant kidney of untreatedweek 2 to 55.5 6 18.7 mg/day at week 8), which remained
stable after treatment withdrawal (68.5 6 18.1 mg/day rats compared with that seen in normal kidney. In fact,
a-SMA expression could be detected as early as the firstat week 12; Fig. 1A).
In treated rats, the plasma creatinine concentration week after subtotal nephrectomy [20] in the interstitium,
preceding the development of tubulointerstitial fibrosis.was lower than in untreated rats at each time period
(Table 1). The creatinine clearance expressed per 100 g Afterward, interstitial a-SMA expression increased
gradually from week 2 to week 8 (surrounding the peritu-kidney weight progressively increased from week 2 to
week 8 in both groups (Fig. 1B), and was higher in the bular and periglomerular spaces) and dramatically be-
tween week 8 and week 12 (Figs. 2A and 3). Interestingly,treated one (from 48.7 6 8.5 at week 2 to 43.5 6 8.7
mL/min/100 g kidney weight at week 12, and from 72.4 6 a-SMA expression was reduced in treated compared
with untreated rats from week 2 to week 8. In addition,4.8 at week 2 to 94 6 6.9 mL/min/100 g of kidney weight
at week 12 in untreated and treated groups, respectively). the number of interstitial a-SMA–positive cells remained
stable after treatment withdrawal from week 8 to weekInterestingly, the MMF-treated rats showed no signifi-
cant changes in creatinine clearance between weeks 8 12 in the treated group, while it continued to increase in
the untreated rats (Fig. 2A). Regression analysis showedthrough 12, while in the untreated group, creatinine
clearance significantly decreased during the same period that a-SMA–positive cells were strongly correlated with
creatinine clearance normalized to kidney weight (r 5(Fig. 1B).
Badid et al: MMF in rat remnant kidney 55
Fig. 1. Proteinuria (A) and creatinine clearance normalized to remnant
kidney weight (B) in mycophenolate mofetil (MMF) treated (s) and
untreated (d) rats during the follow-up period. *P , 0.05 vs. untreated
rats.
Fig. 2. Interstitial a-smooth muscle actin (a-SMA) immunostaining
(A) and type III collagen deposition (B) in treated (h) and untreated
(j) rats during the follow-up period. Values are expressed as a percent-
age of the surface area labeled by the appropriate antibody. *P , 0.05;
***P , 0.005 vs. untreated rats.0.70, P 5 0.0001) and with proteinuria (r 5 0.66, P 5
0.0001) over the 12-week follow-up in both groups.
Collagen deposition
Interstitial collagens stained with Sirius red were sig- were strongly correlated (r 5 0.57, P 5 0.0001). Com-
nificantly reduced in treated compared with untreated pared with untreated rats, the increment of interstitial
rats from week 2 to week 12 (Fig. 4). Moreover, intersti- type III collagen deposition after MMF treatment was
tial type III collagen immunostaining progressively in- lower (Fig. 2B). The deposition of type III collagen in
creased after renal mass reduction in untreated rats, the interstitium was significantly reduced in treated com-
reaching a maximum at the end of follow-up (Fig. 2B). pared with untreated rats. In addition, type III collagen
The increment in type III collagen deposition and the deposition did not increase after treatment withdrawal,
while it kept increasing in the untreated group duringincrement in the number of interstitial myofibroblasts
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Fig. 3. Representative interstitial immunostaining for a-SMA antibody in untreated (on the left) and treated (on the right) rats, at week 2
(A and C) and at week 12 (B and D) after subtotal nephrectomy (3250). Reproduction of this figure in color was made possible by Ezus-Universite´,
Lyon 1, France.
Fig. 6. PCNA-positive cells in untreated (A) and treated (B) rats two weeks after subtotal nephrectomy (3250). Reproduction of this figure in
color was made possible by Ezus-Universite´, Lyon 1, France.
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Fig. 4. Representative interstitial collagens deposition in untreated (on the left) and treated (on the right) rats, determined with Sirius red at
week 12 (A and D, 3100) and with type III collagen monoclonal antibody (mAb) at week 2 (B and E) and at week 12 (C and F), respectively,
after subtotal nephrectomy (3250). Reproduction of this figure in color was made possible by Ezus-Universite´, Lyon 1, France.
the same period (Figs. 2B and 4). Although we have served at the glomerular level for Sirius red staining and
for a-SMA and type III collagen immunostaining.chosen to quantitate the labeling as a fraction of each
optical field, an expression that does not take into ac-
In vivo cell proliferationcount parenchymal volumes, this expression does not
account for the observed differences, since kidney size While no PCNA-positive cells could be seen in normal
in our study was smaller in treated compared to un- rat kidney, PCNA-positive cells reached a maximum two
weeks after subtotal nephrectomy and progressively de-treated rats. Finally, no significant changes were ob-
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Fig. 7. In vitro effect of mycophenolic acid (MPA) on rat fibroblast
proliferation after 72 hours of incubation (in 10% FCS). Cell prolifera-
tion was studied using an MTT assay and the results are expressed as
optical density (at l 5 750 nm). Results are mean 6 SEM of four
independent experiments. *P , 0.001; **P 5 0.0001 vs. control.
creased thereafter (Fig. 5). These proliferating cells were
essentially located in the tubules and the interstitium
and at a lesser degree within the glomeruli (Fig. 6). MMF
treatment reduced the number of PCNA-positive cells
at every period of the study in tubules, glomeruli, and
interstitium.
In vitro fibroblast studies
At concentrations from 1 to 500 mmol/L, the addition
of MPA to cell cultures allowed the fibroblasts to keep
their characteristic morphology as flat elongated cells,
and no reduction of the initial number of cells was ob-
served, indicating that at these doses, there was no cyto-
toxicity. Interestingly, the addition of MPA in the culture
medium induced a dose-dependent decrease in fibroblast
proliferation (Fig. 7).
DISCUSSION
In the present study, we have documented that MMF
treatment significantly improves renal function and re-
duces renal injury after subtotal nephrectomy in rats. In
Fig. 5. Renal expression of glomerular (A), tubular (B), and intersti-
tial (C) proliferating cell nuclear antigen (PCNA)-positive cells in
treated (h) and untreated (j) rats during the follow-up period. *P ,
0.05; **P , 0.01; ***P , 0.005 vs. untreated rats.
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particular, MMF reduces compensatory hypertrophy of withdrawal between weeks 8 and 12, while in untreated
group, interstitial a-SMA staining still increased duringthe remnant kidney and markedly decreases cell prolifer-
ation, myofibroblast infiltration, and collagen III deposi- that same period. Similarly, interstitial collagens were
significantly reduced by MMF treatment. In addition,tion. Interestingly, these changes persist four weeks after
treatment withdrawal. type III collagen deposition was strongly associated with
the number of interstitial myofibroblasts and was signifi-Reduction of renal mass is one of the most widely
used approaches to study mechanisms involved in glo- cantly reduced by MMF. Furthermore, no increment in
interstitial collagen III was observed after treatmentmerulosclerosis. We have performed subtotal nephrec-
tomy by an uninephrectomy followed by an ablation of withdrawal, while it still increased in the untreated group
between weeks 8 and 12. These observations are in accor-the poles in the controlateral kidney. In this excision
model, there is no change in blood pressure during the dance with previous studies, which showed that myofi-
broblasts are involved in a dynamic process leading tofirst weeks, contrasting with the model of renal artery
branch ligation [21, 22]. Moreover, even in this latest the synthesis of extracellular matrix components [25, 26].
Recent observations have shown that MMF attenu-model it has been shown that MMF has no effect on
blood pressure [23]. In addition, treated and untreated ated renal injury in remnant kidney by limiting the accu-
mulation and proliferative activity of lymphocytes andrats received a standard rat chow containing a moderate
amount of protein (16%). Thus, under such experimental macrophages [27, 28]. These inflammatory cells are
known to produce a variety of growth factors and cyto-conditions, we were able to study the effects of early
MMF treatment on the scarring associated with nephron kines [2, 29], which are able to stimulate myofibroblastic
differentiation and proliferation [30, 31]. Thus, attenua-loss alone. In this subtotal nephrectomy model, the scar-
ring process first induces an hypertrophic adaptative re- tion of renal injury by MMF in our study could result
from the reduction of all lymphocyte and macrophagesponse to renal ablation and an initial hyperfiltration,
but this early step is rapidly followed by an exaggerated infiltration [27, 28]. However, our study demonstrates,
to our knowledge for the first time, a direct inhibitoryand maladaptative process. In our study, the remnant
kidney weight and the glomerular volume were lower in effect of MMF on in vitro proliferation of fibroblasts,
and strongly suggests that MMF could ultimately reducetreated than in untreated rats, and the renal function was
improved by MMF treatment. These results are highly the development of fibrosis. Such an antiproliferative
effect has already been shown in vitro for vascularsuggestive of a protective effect of MMF against renal
injury and of an early effect of MMF on glomerular smooth muscle [11–13] and mesangial [32] cells. In vivo
studies have shown that MMF inhibits intimal smoothhypertrophy. These observations are important, as renal
mass hypertrophy is usually related to the development muscle cell hyperplasia after balloon injury [11] and
could decrease the smooth muscle cell proliferation inof renal lesions in experimental subtotal nephrectomy
[21]. On the other hand, the remodeling within tubular animal models of accelerated arteriosclerosis [12]. This
inhibitory effect of MMF on vascular smooth muscleand interstitial cells plays a pivotal role in renal injury,
and in the subtotal nephrectomy model, it is well known cell proliferation has been proposed as a mechanism for
preventing graft rejection by inhibition of obliterativethat the increment of kidney weight depends little on
glomeruli (which form 8% of the renal mass) and mainly arteriopathy [10]. In the same way, the reduction of inter-
stitial myofibroblasts infiltration in treated rats as wellon tubular thickening [21]. In addition, tubular epithelial
cells could play a role in interstitial fibrosis through a as the in vitro antiproliferative effect on rat fibroblasts
suggests a role for this drug in fibrosis development.phenomena called epithelial-mesenchymal transdiffer-
entiation [24], and interestingly, the proliferation of tu- Myofibroblastic differentiation, a pivotal event in the
initiation of fibrosis, is interesting as a prognostic indica-bular cells was markedly reduced by MMF treatment,
which probably contributes to the attenuation of renal tor in human glomerulonephritis [33, 34]. In addition, a
potential therapeutic benefit of MMF in the treatmentinjury.
Under such a context, the secondary important find- of human glomerulonephritis has been suggested [35, 36].
Our in vitro and in vivo results greatly reinforce theseings of this study are the decrease of interstitial myofi-
broblast infiltration strongly associated with the reduc- previous reports. In particular, it is of special interest
that the concentrations of MPA inhibiting the in vitrotion of interstitial type III collagen deposition after MMF
treatment and the persistence of these effects after MMF proliferation of fibroblasts were in the same range than
those observed in patients treated by MMF for pre-withdrawal. Untreated rats showed a progressive incre-
ment of interstitial myofibroblasts, reaching a maximum venting renal graft rejection [37]. Thus, taking all of these
results together, MMF may be able to act on inflamma-at the end of follow-up, while in treated rats, the myofi-
broblast infiltration reached a peak at week 2 and then tory cell activation, which is an early event in the devel-
opment of renal scarring, and on myofibroblast differen-stabilized. Furthermore, no increment of interstitial myo-
fibroblast infiltration was observed after the treatment tiation and proliferation, which are well known to be
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ingham ME, Morris RE: Effects of treatment with cyclosporine,involved in progressive kidney disease and in a large
FK506, rapamycin, mycophenolic acid or desoxyspergualin on vas-
spectrum of fibrocontractive diseases. cular muscle proliferation in vitro and in vivo. Transplant Proc
In summary, MMF significantly improved renal func- 25:770–771, 1993
12. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R,tion parameters and attenuated renal injury following
Billingham ME, Morris RE: Treatment with Rapamycin andsubtotal renal ablation in rats. Furthermore, MMF treat- mycophenolic acid reduces arterial intimal thickening produced
ment led to a marked reduction of interstitial myofi- by mechanical injury and allows endothelial replacement. Trans-
plantation 59:655–661, 1995broblast infiltration resulting in attenuation of interstitial
13. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PLJ: Differentcollagens and particularly of collagen III deposition. On inhibitory effects of immunosuppressive drugs on human and rat
another hand, MPA exhibited an inhibitory effect on aortic smooth muscle and endothelial cell proliferation stimulated
by platelet-derived growth factor or endothelial cell growth factor.proliferation of rat fibroblasts. Thus, our results strongly
J Heart Lung Transplant 16:484–492, 1997suggest that MMF may be useful in preventing the course 14. Shimamura T, Morrison AB: A progressive glomerulosclerosis
of progressive renal disease toward end-stage renal occurring in partial five-sixths nephrectomy. Am J Pathol 79:95–
101, 1975failure.
15. Weibel ER: Stereological methods, in Practical Methods for Bio-
logical Morphometry, vol 1, edited by Weibel ER, London, Aca-
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